NEW YORK, April 6, 2011 /PRNewswire/ — The U.S. Food and Drug
Administration announced on March 31 that it had cleared
Mandometer® for the treatment of patients with eating
disorders.
Mandometer® is an innovative device that provides
biofeedback allowing individuals to monitor their rate of eating
and their development of satiety during meals and in comparison to
those eating normally. Once patients learn to adapt to a normal
eating pattern, they are able to normalize their body weight.
The device has been shown to be effective through randomized
clinical trials for the treatment of eating disorders. Those
trials have demonstrated that 75 percent of the patients treated
with the Mandometer® method recover and 90 percent remain
healthy over five years.
This breakthrough program was developed by Cecilia Bergh, Ph.D.,
and Per Sodersten, Ph.D., two researchers at the world-renowned
Swedish academic health center, the Karolinska Institute in
Stockholm, Sweden.
Dr. Bergh and Dr. Sodersten founded the company Mando Group AB
to establish clinics that utilize the Mandometer® method to
treat eating disorders. Currently, there are already
Mandometer® clinics in Sweden, in Australia and one on East
78th Street in New York.
As a result of the issue of the FDA clearance, physicians can
prescribe therapy by the Mandometer® method.
Cecilia Bergh is CEO of Mando Group AB and is also executive
director of the Mandometer® Clinics. Per Sodersten
is professor of Behavioral Neuroendocrinology at the Karolinska
Institute.
To observe the Mandometer® being used, visit:
http://www.mando.se/en/Media-archive–/Information-films–/Information-films-/1.aspx
To learn more about Mandometer® go to www.mandometer.co
‘/>”/>
